Lymphocyte Subsets
(n = 33)

Groups

ALN Median (Range)

P Value^{(g)}


CD4^{+}

Non metastatic ALNs (n = 9)

63.0 (43.074.0)^{(e)}

0.796

Metastatic ALNs (n = 24)

68.0 (32.075.0)

CD8^{+}

Non metastatic ALNs (n = 9)

26.0 (15.434.0)^{(e)}

0.121

Metastatic ALNs (n = 24)

20.5 (10.440.0)

FOXP3^{+}

Non metastatic ALNs (n = 9)

4.4 (2.98.6)^{(e)}

0.736

Metastatic ALNs (n = 24)

4.6 (0.210.8)

CTLA4^{+}

Non metastatic ALNs (n = 9)

16.8 (5.2100.4)^{(f)}

0.193

Metastatic ALNs (n = 24)

11.0 (0.638.6)

PD1^{+ (d)}

Non metastatic ALNs (n = 9)

6.4 (1.436.0)^{(f)}

0.408

Metastatic ALNs (n = 7)

12.6 (2.072.6)

CD56^{+}

Non metastatic ALNs (n = 9)

17.8 (15.852.8)^{(f)}

0.437

Metastatic ALNs (n = 24)

18.3 (2.260.4)

 ^{(a)} ALNs: Axillary lymph nodes (paracortical areas: tumour deposits are excluded if present); ^{(b)} LLABCs: Large and locally advanced breast cancers; ^{(c)}NAC: Neoadjuvant chemotherapy; ^{(d)} PD1^{+}: Programmed death1 (n = 16); ^{(e)}Average percentage of positively stained cells out of all the lymphoid cells in the ALN sections examined; ^{(f)} Average cell count of positively stained cells per 400× highpower field in the ALN sections examined; ^{(g)} MannWhitney U test